Allurion Gastric Balloon System
Allurion Technologies, Inc. · Decision date Sep 9, 2026
What did the FDA approve?
FDA records P250023/S001 as a supplement to PMA P250023, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 9, 2026.
FDA approval order statement
revisions to the patient labeling, physician labeling and patient information card to enhance product safety information
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 9, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P250023/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Allurion Technologies, Inc.
- Product code
- LTI
- Decision code
- APPR
- Decision date
- Sep 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.
- Applicant
- Allurion Technologies, Inc.
- Product code
- LTI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250023 · Original PMA
Allurion Gastric Balloon System
P250023/S001 received
Application receipt date recorded by FDA.
P250023/S001 · FDA decision
Special (Immediate Track)
P250023/S002 · Related supplement
Allurion Gastric Balloon System
Timeline entries are records held by MedtechLedger for P250023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Allurion Technologies, Inc. | PMA approval | Feb 20, 2026 | FDA | |
Allurion Gastric Balloon SystemP250023/S002 | Allurion Technologies, Inc. | PMA supplement | Sep 23, 2026 | FDA |
Explore the linked device profile
Other records with product code LTI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ORBERA INTRAGASTRIC BALLOONP140008/S028 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jan 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allurion Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11 Huron Dr., Natick, MA, 01760
Sources and methodology
- Original FDA record: P250023/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

